SCHEDULE 13G/A: BlackRock Amends MacroGenics Stake, Reports 2.9% Passive Ownership

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 2.9% passive beneficial ownership stake in MacroGenics Inc. common stock as of June 30, 2025.

Summary

• BlackRock, Inc. filed Amendment No. 11 to Schedule 13G concerning its beneficial ownership in MacroGenics Inc.
• As of June 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 1,813,695 shares of MacroGenics Inc. Common Stock.
• This ownership represents 2.9% of the total outstanding class of securities.
• BlackRock holds sole voting power over 1,808,028 shares and sole dispositive power over 1,813,695 shares.
• No shared voting or dispositive power is reported by BlackRock.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MacroGenics Inc.
• No single person or subsidiary within BlackRock's reporting business units holds more than five percent of MacroGenics Inc.'s total outstanding common shares.

Sentiment

Score: 6

Explanation: The document is neutral in tone, reporting a routine passive ownership stake. The 2.9% stake is not particularly significant, but the continued holding by a major institutional investor like BlackRock is generally a stable sign, albeit without indicating strong positive or negative sentiment towards the issuer's performance.

Positives

• BlackRock's continued passive investment indicates a long-term, non-activist interest in MacroGenics Inc.
• The holding is for investment purposes in the ordinary course of business, suggesting no immediate intent to influence control or engage in activist campaigns.

Negatives

• The reported ownership of 2.9% is below the 5% threshold, indicating a relatively small stake for a major institutional investor like BlackRock.
• The document does not provide any positive financial or operational updates for MacroGenics Inc. itself, as it is solely a beneficial ownership report.

Risks

• The document does not detail specific risks related to MacroGenics Inc.'s operations or financial health, as it is a beneficial ownership report.
• The filing does not indicate any intent by BlackRock to increase its stake, which could be a potential risk if the company were seeking a larger institutional anchor investor.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding MacroGenics Inc.'s business operations or financial performance. It solely reports BlackRock, Inc.'s beneficial ownership stake.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a routine disclosure of passive institutional ownership by BlackRock, Inc., a major global asset manager. It reflects BlackRock's investment strategy in the biotechnology or pharmaceutical sector, where MacroGenics Inc. operates. Such filings are common and indicate ongoing portfolio management by large funds.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for institutional investors holding less than 5% of a company's outstanding shares with a passive investment intent.
• BlackRock, Inc. is one of the world's largest asset managers, and its holdings in various companies, including those in the biotechnology sector like MacroGenics Inc., are typical for its diversified investment portfolios.
• The 2.9% stake is a relatively small position for BlackRock compared to its larger holdings in other companies, but consistent with a passive, diversified investment approach.
• No specific comparable companies, projects, or results are mentioned in the document to allow for a direct comparison of MacroGenics' performance or results.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, confirming a passive investment approach.
• Management: Awareness of BlackRock's continued, albeit passive, investment.

Next Steps

• BlackRock, Inc. will continue to monitor its investment in MacroGenics Inc.
• Future Schedule 13G amendments will be filed if there are significant changes in beneficial ownership (e.g., crossing 5% threshold, or significant changes in percentage owned).

Key Dates

Recommendation

Keywords

MacroGenics Inc, BlackRock Inc, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, MGEN